Clear Eyes Supply Tightens, Prestige Cuts Forecast

Retailers and suppliers carrying Clear Eyes should expect reduced availability in the second half of fiscal 2027.

Updated on Nov. 6, 2026 in Consumer Goods

Clear Eyes Supply Tightens, Prestige Cuts Forecast

Prestige Consumer Healthcare lowered its fiscal 2027 revenue and adjusted earnings forecasts on November 5, citing recent production variability in Clear Eyes at Pillar5. Revised revenue guidance is $1.280 billion to $1.290 billion, down from $1.290 billion to $1.315 billion, affecting eye-care product suppliers and retail channels that carry the brand.

Why it matters

The revision reflects a supply-side constraint rather than weak demand: Pillar5 production variability is expected to reduce Clear Eyes availability and revenue in the second half of fiscal 2027. For operators in consumer health and pharmacy retail, supply continuity on a single brand can shift shelf planning and promotional timing.

Quarterly revenue rose 22.7% to $336.307 million, but fell 1.6% excluding the Breathe Right and LaCorium acquisitions, which contributed $65.083 million. The company cut its organic growth outlook from 1% to 3% to roughly flat and lowered its adjusted free cash flow target to at least $265 million from at least $270 million.

The players

Prestige Consumer Healthcare

A branded over-the-counter healthcare company whose portfolio includes Clear Eyes and Breathe Right, sold through mass retail and pharmacy channels.

Pillar5

The production site whose manufacturing variability is reducing Clear Eyes availability, according to the company.

The details

Prestige attributed the forecast cut to recent variability in Clear Eyes production at its Pillar5 facility, which is expected to reduce product availability in the second half of fiscal 2027. Because acquisitions drove the reported top-line increase, the underlying business contracted slightly on an organic basis. The revised guidance narrows the revenue range and trims the adjusted EPS range, reflecting the lower expected volume from the affected brand.

Timeline

  1. June 2026: Breathe Right acquisition closed.

  2. July 2026: LaCorium acquisition closed.

  3. September 30, 2026: Fiscal second quarter ended.

  4. November 5, 2026: Company revised fiscal 2027 revenue and EPS forecasts.

Market Landscape

Prestige's revised guidance lowers its own earlier fiscal 2027 range, turning an expected modest organic gain into roughly flat growth. The correction shows how a single manufacturing site can reset guidance for a branded over-the-counter portfolio that relies on acquisitions to lift reported revenue.

Operators in pharmacy and mass retail should review reorder schedules and shelf allocation for Clear Eyes, since availability is expected to tighten in the second half of fiscal 2027. Suppliers and distributors tied to the brand should revisit delivery commitments against the revised revenue outlook.

The takeaway

Treat single-site production risk as a live planning variable when a brand represents a large share of a category's shelf space. Track the company's next quarterly filing for a clearer read on how much second-half Clear Eyes revenue is actually lost.

Further reading

For broader context on how production issues move branded goods forecasts, see Consumer Goods coverage.

Source note: This article includes information reported by TokenPost.